(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 10.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.46%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.88%.
Moderna's revenue in 2026 is $2,228,000,000.On average, 26 Wall Street analysts forecast MRNA's revenue for 2026 to be $850,771,679,459, with the lowest MRNA revenue forecast at $758,148,953,211, and the highest MRNA revenue forecast at $966,550,087,269. On average, 25 Wall Street analysts forecast MRNA's revenue for 2027 to be $987,310,353,497, with the lowest MRNA revenue forecast at $757,749,717,322, and the highest MRNA revenue forecast at $1,327,858,566,814.
In 2028, MRNA is forecast to generate $1,229,646,538,120 in revenue, with the lowest revenue forecast at $857,558,689,572 and the highest revenue forecast at $1,901,161,303,418.